Drug Como Tolerated In Lung And Breast Cancer Patients Shows Positive Response For Hodgkin’s Disease In Young Adults

New research published in the latest print edition of the Journal of Clinical Oncology (Vol. 27, No. 9) shows a treatment combination used in breast and lung cancers to be effective against Hodgkin’s disease in pre-teens and young adults. Richard Drachtman, MD, the interim chief and medical director of the Division of Pediatric Hematology/Oncology at […]

Former Irish President Mary Robinson To Chair LIVESTRONG(TM) Global Cancer Summit

The Lance Armstrong Foundation (LAF) announced that Mary Robinson, the first female President of Ireland and former United Nations High Commissioner for Human Rights, will serve as Honorary Chairperson of the LIVESTRONG Global Cancer Summit. The Summit, to be held in Dublin, Ireland August 24-26, 2009, is the landmark event of the LIVESTRONG Global Cancer […]

Pioneering Cancer Prevention Program Launched In New York

A prevention program serving an ethnically diverse population of women at high risk of cancer is detailed in an article published Monday 23 March in the online peer-reviewed journal ecancer. The article describes a screening program to identify women from underserved communities who are at a high risk of developing breast or ovarian cancer; a […]

Hollow Gold Nanospheres Show Promise For Biomedical And Other Applications

A new metal nanostructure developed by researchers at the University of California, Santa Cruz, has already shown promise in cancer therapy studies and could be used for chemical and biological sensors and other applications as well. The hollow gold nanospheres developed in the laboratory of Jin Zhang, a professor of chemistry and biochemistry at UCSC, […]

Latest Data On UK Cancer Survival Fuel Debate Over Effectiveness Of NHS Cancer Plan For England

The National Health Service (NHS) cancer plan for England shows some beneficial effect on survival, although wide regional variations remain; more follow-up data are needed before the true impact of the cancer plan can be fully established. These are the conclusions of the first study to assess whether the cancer plan is working, published in […]

Breast tissue evaluation with fine-needle aspiration fast tracks cancer Rx planning

BARBARA BOUGHTON Despite its limitations, FNA offers lower cost, less invasion, and fewer complications. Experts discuss why they chose FNA over core biopsy. In the past decade, core biopsy has largely replaced fine-needle aspiration for breast tissue evaluation. The latter technique’s inability to distinguish between invasive cancer and in situ cases and a general unease […]

Anthracycline Cardiotoxicity: Why Are We Still Interested?

Anthracycline cardiotoxicity has been of clinical concern for more than 3 decades. Many hundreds of papers have been written about this unusual form of toxic cardiomyopathy, and yet, we are still putting pieces of the puzzle together. Our cumulative knowledge helps us to predict the risk of cardiac damage with fair accuracy for most patients, […]

Anthracycline-­Induced Cardiotoxicity: Risk Assessment and Management

In the current issue of ONCOLOGY, Hershman and Shao provide a comprehensive review of anthracycline-induced cardiotoxicity (AIC). Risk factors for AIC include age (??18 or ??65 years) at time of treatment, increasing cumulative dose or dose intensity of anthracyclines, mediastinal radiation therapy (RT), and female gender.[1-4] The Surveillance, Epidemiology and End Results (SEER)-Medicare database showed […]

The Challenges of Improving Breast Cancer Outcome With Diagnostic Imaging Techniques

Positron-emission tomography (PET) technology has drastically improved in the past few years, with the development of hybrid imaging devices combining PET and computed tomography (CT), which have essentially replaced stand-alone PET scanners in most centers. Image quality has also increased with the use of improved PET detectors and image reconstruction techniques. While a few years […]

ARIMIDEX Offers Women Greater Protection Against HR+ Early Breast Cancer Returning In The 1st 2 Yrs

“Anastrozole is the only aromatase inhibitor (AI) which has now been shown to prevent recurrences in women with hormone receptor positive early breast cancer both during the initial high-risk two years after surgery, and also well beyond the completion of treatment. In breast cancer there are no guarantees and we can’t predict which women will […]